New drug combo aims to beat CMV in kidney transplants

NCT ID NCT06334497

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding letermovir to the standard drug valganciclovir works better than valganciclovir alone for treating CMV infections in kidney transplant recipients. About 80 adults who have a kidney transplant and a CMV infection will take part. The goal is to see if the combination lowers the virus faster and more safely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTION

Contacts and locations

Locations

Centre 011-Hôpital Bichat, Service de Néphrologie
RECRUITING

Paris, Île-de-France Region, 75018, France
Hôpital Européen Georges Pompidou
RECRUITING

Paris, Île-de-France Region, 75015, France
Hôpital Necker Enfants Malades
RECRUITING

Paris, 75015, France
Hôpital Necker Enfants Malades - SMIT
RECRUITING

Paris, Île-de-France Region, 75015, France
Hôpital de la Pitié Salpêtrière, Service de Néphrologie
RECRUITING

Paris, Île-de-France Region, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.